Winton Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Winton Group’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-22,504	Closed	-$391K	–	801
2023 Q3	$391K	Buy	+22,504	New	+$379K	0.03%	380

Other funds holding KNSA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Winton Group's KNSA Position: Q4 2023 in Review

Winton Group sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2023, closing a stake of 22,504 shares — an estimated $391K sold.

Winton Group first reported a position in KNSA in Q3 2023 and held it in 1 quarter. The position peaked at $391K in Q3 2023. 142 funds tracked by Wall St. Rank hold KNSA as of Q4 2023.

Winton Group reported no remaining Kiniksa Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Winton Group sold 22,504 Kiniksa Pharmaceuticals shares in Q4 2023, an estimated $391K.
Winton Group first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and held it in 1 quarter.
Winton Group's Kiniksa Pharmaceuticals position peaked at $391K in Q3 2023.
142 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2023.

Based on Winton Group's 13F filing for Q4 2023, filed 12 Feb 2024.